Joby Aviation closes $591 million stock offering with full underwriter option
ESTERO, FLORIDA - Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP), a micro-cap biotech company with a market capitalization of $19 million, announced Monday it has filed an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual drug delivery technology. The stock has shown significant volatility, gaining nearly 23% in the past week despite being down 97% year-to-date, according to InvestingPro data.
The application seeks to protect the company’s proprietary system designed to enhance pharmacokinetic performance of active pharmaceutical ingredients by improving bioavailability and speed of onset when administered under the tongue.
According to the company, the technology allows for rapid absorption through sublingual blood vessels, bypassing first-pass metabolic processes and avoiding exposure to the acidic environment of the stomach and gastrointestinal tract.
"The filing of this omnibus patent application for our sublingual delivery platform marks another important step in strengthening our intellectual property portfolio among many classes of drugs," said Kraig Higginson, Interim Chief Executive Officer of Aspire, in a press release statement.
The omnibus application focuses exclusively on the company’s sublingual delivery system and aims to expand protection across various drug classes beyond patents already filed by Aspire.
The company states its technology can be applied to both small and large molecule therapeutics, as well as nutraceuticals and supplements.
Aspire Biopharma Holdings develops drug delivery technology that enables rapid and precise administration of medications. The company is traded on the Nasdaq under the ticker ASBP, currently priced at $0.38 per share. Discover more financial metrics and insights about ASBP with InvestingPro, which offers 8 additional key investment tips for this stock.
In other recent news, Aspire Biopharma Holdings, Inc. announced significant developments in its drug delivery technology pipeline, with plans to submit a New Drug Application for its sublingual high-dose aspirin formulation in the second half of 2025. Recent clinical trials have demonstrated that this formulation achieves higher and faster plasma concentrations compared to traditional aspirin tablets, with rapid inhibition of serum thromboxane B2, a marker for blood clot formation. Aspire Biopharma has also completed a $1 million funding tranche as part of a larger Securities Purchase Agreement, bringing total funding to $5,709,677 out of a planned $7,750,000. The company recently changed its independent registered public accounting firm, as disclosed in a recent SEC filing. Additionally, Aspire has launched a new e-commerce platform, buzzbomb.buzz, to sell its sublingual caffeine product, BUZZ BOMB, aimed at providing rapid energy for athletes and fitness enthusiasts. The company has entered into a $9.7 million note purchase agreement, with notes convertible into common stock starting 31 days post-issuance. These notes carry a 20% original issue discount and mature in February 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.